|
| PLURISTEM THERA - Fundamental Profile | |
|
| Company Information |
| Ticker Symbol: |
PSTI |
| Exchange: |
NASD |
| Contact Info: |
MATAM Advanced Technology Park
Haifa 31905
972 7 4710 7171 |
| CEO/President: |
Zami Aberman |
Industry,Sector,
Index: |
SIC: 7374, Medical - Biomedical
|
| Description: |
PLURISTEM THERAPEUTICS INC. is a bio-therapeutics company dedicated to the commercialization of non-personalized (allogeneic) cell therapy products for the treatment of several severe degenerative, ischemic and autoimmune disorders. The Company is developing a pipeline of products, stored ready-to-use, that are derived from the human placenta, a non-controversial source, and not from embryonic stem cells. |
|
| Share Information |
| Market Value, $K: |
23,210 |
Shares Outstanding, K: |
8,400 |
| % Held by Insiders: |
10.00% |
% Institutional Shareholders: |
1.84% |
| Last Quarter Sales, $M: |
0.00 |
Last Quarter Net Income, $M: |
-0.80 |
| Last Quarter EPS: |
N/C |
P/E Ratio: |
0.00 |
| Annual EPS, $: |
0.00 |
Most Recent Earnings, $: |
|
| Annual Dividend Rate, $: |
0 |
Most Recent Dividend: |
|
| Annual Dividend Yield, %: |
0% |
Most Recent Split: |
1-175 on 11/26/07 |
|
Fundamental information provided by Zacks Investment Research, Inc.
Zacks does not represent, warrant,
or guarantee completeness, accuracy or timeliness of its data, and shall have no liability of any kind whatsoever
to any party on account of any incompleteness of, inaccuracies in or untimeliness of the Zacks content provided
hereunder, or for any delay in reporting such data. Zacks expressly disclaims all warranties of fitness of the
Zacks content or computations and analyses thereof for a particular purpose or use.
|
|
|
| Data provided by ddfplus and subject to terms of use. Copyright © 1995 - 2010 Barchart.com Inc. User agreement applies. |
All Equities data is delayed according to exchange rules. Futures data is end of day.
NYSE, AMEX and Nasdaq at least 15 minutes. |
|
